Pfizer Inc. (NYSE:PFE) Stake Cut by O ROURKE & COMPANY Inc

O ROURKE & COMPANY Inc cut its position in shares of Pfizer Inc. (NYSE:PFE) by 33.6% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,651 shares of the biopharmaceutical company’s stock after selling 5,398 shares during the quarter. O ROURKE & COMPANY Inc’s holdings in Pfizer were worth $296,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in PFE. Advisor OS LLC lifted its stake in Pfizer by 1.0% in the fourth quarter. Advisor OS LLC now owns 35,202 shares of the biopharmaceutical company’s stock valued at $1,013,000 after buying an additional 365 shares during the last quarter. Safeguard Investment Advisory Group LLC lifted its stake in Pfizer by 3.9% in the fourth quarter. Safeguard Investment Advisory Group LLC now owns 9,987 shares of the biopharmaceutical company’s stock valued at $288,000 after buying an additional 371 shares during the last quarter. Lantz Financial LLC lifted its stake in Pfizer by 1.3% in the first quarter. Lantz Financial LLC now owns 30,582 shares of the biopharmaceutical company’s stock valued at $849,000 after buying an additional 381 shares during the last quarter. King Wealth Management Group lifted its stake in Pfizer by 2.4% in the fourth quarter. King Wealth Management Group now owns 16,686 shares of the biopharmaceutical company’s stock valued at $480,000 after buying an additional 388 shares during the last quarter. Finally, Advance Capital Management Inc. lifted its stake in Pfizer by 4.0% in the fourth quarter. Advance Capital Management Inc. now owns 10,177 shares of the biopharmaceutical company’s stock valued at $293,000 after buying an additional 391 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Performance

PFE traded up $0.24 on Monday, hitting $28.22. The company had a trading volume of 24,982,110 shares, compared to its average volume of 40,791,203. The company’s fifty day moving average price is $27.90 and its 200 day moving average price is $27.69. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $37.80. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78. The stock has a market cap of $159.91 billion, a price-to-earnings ratio of -470.25, a price-to-earnings-growth ratio of 1.10 and a beta of 0.69.

Pfizer (NYSE:PFE) last posted its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping the consensus estimate of $0.56 by $0.26. The firm had revenue of $14.88 billion during the quarter, compared to analyst estimates of $13.87 billion. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The company’s revenue for the quarter was down 19.5% on a year-over-year basis. During the same period in the previous year, the company earned $1.23 EPS. Equities analysts predict that Pfizer Inc. will post 2.38 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be given a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 5.95%. The ex-dividend date is Friday, July 26th. Pfizer’s dividend payout ratio is currently -2,799.53%.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research note on Wednesday, June 26th. BMO Capital Markets restated an “outperform” rating and set a $36.00 price objective (up from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Morgan Stanley lifted their price objective on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday, May 2nd. Finally, Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Nine equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and an average price target of $35.54.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.